Also listed on Botulinum Toxin Research Associates, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Collateral for a security interest recorded Feb 7, 2025 (Hayfin Services LLP).
Term ends Dec 4, 2029 · High confidence
20-year base term ends Dec 4, 2029
Held by Revance Therapeutics, Inc.
Filed Jun 29, 2015 as application 14/754,268 · Granted Apr 24, 2018
Base term, 20 years from filing
Today
2009
2029
Clock starts
Dec 4, 2009
Dec 4, 2009
Term ends
Dec 4, 2029
Dec 4, 2029
Granted
Apr 24, 2018
Apr 24, 2018
base term
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 2 of 2 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 4, 2009, when application PCT/US2009/066891, the earliest non-provisional in its chain, was filed (this one was filed Jun 29, 2015) | Dec 4, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 4, 2029 | High confidence |
This family
| Application PCT/US2009/066891 | PCT application no patent term | no patent term |
| US 9,066,851 | In force Sep 2031 | Sep 2031 |
| US 9,950,042 | this patent Dec 2029 | Dec 2029 |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 24, 2016 Reel 38249, frame 590 | Borodic, Gary e, DR | Botulinum Toxin Research Associates, Inc. | Assignment of Assignor's Interest |
| Jun 3, 2016 Reel 38870, frame 160 | Botulinum Toxin Research Associates, Inc. | Revance Therapeutics, Inc. | Assignment of Assignor's Interest |
| Mar 18, 2022 Reel 59437, frame 654 | Revance Therapeutics, Inc. | Athyrium Buffalo LP | Security Interest |
| Feb 7, 2025 Reel 70153, frame 630 | Athyrium Buffalo LP | Revance Therapeutics, Inc. | Release of Security Interest |
| Feb 7, 2025 Reel 70153, frame 663 | Revance Therapeutics, Inc.; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 7, 2025 Reel 70153, frame 736 | Revance Therapeutics, Inc.; Bellus Medical, LLC; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 17, 2025 Reel 70239, frame 739 | Revance Therapeutics, Inc. | Jpmorgan Chase Bank, N.a. | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Dec 2029
Term ends Dec 4, 2029. No further fees fall due before then
Citations
9
later US patents cite this one
That is above the median of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.